Guideline / position statementindependent cross-checkabstract only checked I-PPI-05 standard review
Canadian guideline for stopping PPIs
Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.
Overview
Farrell B et al.. Can Fam Physician 2017 · PMID 28500192
PPIs can be reduced or stopped in many patients, but not in Barrett's, severe oesophagitis or after bleeding ulcers.
Does the study support the specific claim? Partly · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Deprescribing.
- How was the study done?
GRADE guideline.
- What was actually found?
Deprescribe eligible patients.
- What do the results mean in everyday life?
Stopping is possible.
- What are the study's limitations?
Abstract only.
- What does it say about Elawady's specific claim?
Contradicts 'cannot stop' and universal ban.
- Do the results apply to Germany and Europe?
Applicable.
Scientific in-depth review
1. Full reference
- Authors
- Farrell B et al.
- Journal
- Can Fam Physician
- Year
- 2017
- Identifier
- PMID 28500192
- Verification
- verified – PubMed efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
When and how to taper or stop PPIs
3. Study design and population
- Study design
- Guideline / position statement – Evidence-based clinical practice guideline (GRADE) with systematic review of de-prescribing trials
- Population
Adults on PPIs ≥4 weeks for heartburn/mild–moderate GERD/oesophagitis with resolved symptoms
- Country
Canada
- Period
2017
- Inclusion and exclusion criteria
Excludes Barrett's, grade C/D oesophagitis, bleeding ulcer history
4. Methods and endpoints
- Exposure / intervention
Dose reduction, stop, on-demand use
- Comparator
Continuation
- Endpoints
Symptom control; harms
- Statistical methods
GRADE
5. Actual results
- Results
Recommends de-prescribing (reduce dose, stop, or on-demand) in eligible adults; recommendations do not apply to Barrett's, severe oesophagitis or bleeding ulcer history.
- Absolute risks
not applicable
- Authors' conclusion
Practical recommendations to support, not dictate, decisions.
6. Strengths
- GRADE
- Systematic review of trials
7. Weaknesses
- Abstract only read
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Guideline.
9. Assessment of the statistical interpretation
10. Relevance to the specific claim
C-PPI-07, -10, -11.
11. Independent contrary findings
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
Shows de-prescribing is feasible in suitable patients.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- PPIs create dependency: the drug 'manufactures the disease it claims to treat', so that a short course for a passing complaint turns into chronic dependence and one 'cannot stop'. – Studies contradicting or limiting the claim
- All acid-suppressing medicines (PPIs and H2 blockers) are permanently forbidden; heartburn should stop through the diet, not through drugs. – Studies contradicting or limiting the claim
- PPIs are widely prescribed without a real indication (for example by doctors of other specialties to 'protect the stomach') and are now sold freely. – Studies supporting the claim